1-10 of 10
Jeremy Ross
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

Free
Aarif Ahsan, Christine Mantis, Adam Luo, Pingping Zheng, Wei Liu, Catherine Zhang, Cesar Rodriguez, Peter Voorhees, Anita D'Souza, Alfred Chung, Sascha Tuchman, Hana Safah, John Mckay, Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, Shaji Kumar, Muhamed Baljevic, Hira Mian, Rajvineeth Kumar Pothacamury, Anders Svensson, Chetasi Talati, Jeremy Ross
Journal: Blood
Blood (2025) 146 (Supplement 1): 2204.
https://doi.org/10.1182/blood-2025-2204
Published: 2025
Journal Articles

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

Free
Aarif Ahsan, Adam Luo, Cesar Rodriguez Valdes, Peter Voorhees, Anita D'Souza, Alfred Chung, Sascha Tuchman, Hana Safah, John Mckay, Katja Weisel, Raphael Teipel, Neha Korde, Ravi Vij, Shaji Kumar, Thomas Doerr, Rajvineeth Kumar Pothacamury, Chetasi Talati, Brenda Chyla, Jeremy Ross
Journal: Blood
Blood (2025) 146 (Supplement 1): 5813.
https://doi.org/10.1182/blood-2025-5813
Published: 2025
Journal Articles

T-cell engager activity of etentamig (BCMA x CD3) is potentiated by daratumumab in preclinical models of multiple myeloma

Free
David Sharon, Valerie Robinson, Durga Dandamudi, Michelle Belmont, Jeremy Ross, PK Epling-Burnette, Aarif Ahsan
Journal: Blood
Blood (2025) 146 (Supplement 1): 2259.
https://doi.org/10.1182/blood-2025-2259
Published: 2025
Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Free
Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3131.
https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131
Published: 2017
Journal Articles

Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Free
Philippe Moreau, Asher A. Chanan-Khan, MD, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, MD, Shaji Kumar, MD, Cyrille Touzeau, Jaclyn Cordero, Jeremy Ross, Wijith Munasinghe, Jia Jia, Ahmed H. Salem, Joel Leverson, Paulo Maciag, Maria Verdugo, Simon J. Harrison
Journal: Blood
Blood (2016) 128 (22): 975.
https://doi.org/10.1182/blood.V128.22.975.975
Published: 2016
Journal Articles

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Free
Shaji Kumar, MD, Ravi Vij, MD, Jonathan L. Kaufman, MD, Joseph Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, Cristina Gasparetto, MD, Martine Amiot, Philippe Moreau, Stefanie Alzate, Jeremy Ross, Martin Dunbar, Tu Xu, Suresh Agarwal, Joel Leverson, Paulo Maciag, Maria Verdugo, Cyrille Touzeau
Journal: Blood
Blood (2016) 128 (22): 488.
https://doi.org/10.1182/blood.V128.22.488.488
Published: 2016
Journal Articles

A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax

Free
Jenny Wu, Jeremy Ross, Franklin V. Peale, Jr., John D Shaughnessy, Jr., PhD, Ryan K Van Laar, PhD, Gareth J Morgan, MD PhD, Jeffrey M Venstrom, Elizabeth A. Punnoose, PhD
Journal: Blood
Blood (2016) 128 (22): 5613.
https://doi.org/10.1182/blood.V128.22.5613.5613
Published: 2016
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Free
Shaji K. Kumar, MD, Ravi Vij, MD MBA, Jonathan L. Kaufman, MD, Joseph R. Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lotfi Benboubker, MDPhD, Philippe Moreau, MD, Martine Amiot, PhD, Stefanie Alzate, MS, Lura Morris, BA, Jeremy Ross, PhD, Martin Dunbar, DrPH, Ming Zhu, PhD, Paulo Maciag, MD, Suresh Agarwal, PhD, Joel Leverson, PhD, Sari Heitner Enschede, MD, Rod A. Humerickhouse, MD PhD, Cyrille Touzeau, MD
Journal: Blood
Blood (2015) 126 (23): 4219.
https://doi.org/10.1182/blood.V126.23.4219.4219
Published: 2015
Journal Articles

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Free
Jeremy Ross, PhD, Martine Amiot, PhD, Brenda Chyla, PhD, Lisa Roberts-Rapp, Rasna Goswami, Sun Yan, Xin Huang, Anahita Bhathena, Sari Heitner Enschede, MD, Paulo Maciag, MD, Rod A. Humerickhouse, MD PhD, Evelyn McKeegan
Journal: Blood
Blood (2015) 126 (23): 2975.
https://doi.org/10.1182/blood.V126.23.2975.2975
Published: 2015
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Free
Philippe Moreau, MD PhD, Asher Chanan-Khan, MD, Andrew W. Roberts, MBBS, PhD, Amit B. Agarwal, MDPhD, Thierry Facon, Shaji Kumar, MD, Cyrille Touzeau, MD, David Darden, MS, Lura Morris, BA, Jeremy Ross, PhD, Ahmed H Salem, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Joel Leverson, PhD, Paulo Maciag, MD, Sari Heitner Enschede, MD, Maria Verdugo, MD, Rod A. Humerickhouse, MD PhD, Simon Harrison, MD
Journal: Blood
Blood (2015) 126 (23): 3038.
https://doi.org/10.1182/blood.V126.23.3038.3038
Published: 2015